Citations

12007 Background: YAs with cancer, defined as those diagnosed prior to the age of 40, may experience greater symptom burden compared to those diagnosed at older ages. We evaluated the impact of an ePROM-triggered, CC-based, supportive care intervention on symptom burden in YAs with cancer. Methods: The Enhanced, Electronic Health Record-facilitated Cancer Symptom Control (E2C2) trial was a cluster-randomized, pragmatic trial (NCT03892967) that enrolled oncology patients seen at Mayo Clinic Rochester and within the Mayo Clinic Health System (sites in Minnesota and Wisconsin) between March 2019 and January 2023. Patients routinely reported the severity of six SPPADE symptoms (Sleep deficit, Pain, Physical function impairment, Anxiety, Depression, and Energy deficit/fatigue) on 11-point numerical rating scales. Symptom severity was classified as none to mild (0-3), moderate (4-6), or severe (7-10). Those with moderate or severe symptoms were offered symptom management education, while those with severe symptoms were also offered the option to work virtually with a symptom care manager. In this post hoc analysis, we examined the effects of the intervention on change in symptom scores among YAs and time to improvement to a mild/moderate level in those with at least one severe symptom. Results: Among 40,659 patients who responded to at least one survey, 2,598 were YAs and 38,061 were adults ≥ 40 years. Among YAs, 10.7%, 24.3%, and 65.1% were 18-24 years, 25-31 years, and 32-39 years, respectively. A greater proportion of YA patients were female (61.5% vs 57.0%), of a non-white race (12.4% vs 5.3%), living in an urban setting (65.7% vs 55.1%), single (36.4% vs 9.6%), on non-government insurance (78.1% vs 36.6%), employed (72.6% vs 37.4%), and had a Bachelor’s degree or greater (37.8% vs 28.3%, p < 0.001 for all). Fewer YA patients had metastatic disease compared to older patients (24.2% vs 35.2%, p < 0.001). Compared to a pre-intervention baseline, the mean change in symptom score for YA patients following the intervention demonstrated improvements in anxiety (-0.195) and depression (-0.168, p < 0.0001 for both), while physical function impairment worsened over the intervention period (0.101, p = 0.014). Compared to adults ≥ 40 years, YAs experienced greater intervention effects for management of depression ( p < 0.001), fatigue ( p = 0.01), pain ( p < 0.0001), and physical function impairment ( p < 0.0001). Among YAs with a severe symptom during the intervention period, median time to improvement to a mild/moderate level was longer for anxiety compared to those ≥ 40 years (3.5 vs 2.7 months, p = 0.009). Conclusions: Routine ePROM surveillance, coupled with CC-based symptom management, led to improvements in anxiety and depression among YAs with cancer, although, time to improvement was longer for anxiety compared to adults ≥ 40 years.

Abstract Background Breast cancer (BC) survivors frequently experience sleep disturbances, which may persist for many years after treatment. This study aimed to describe trends in sleep-related symptoms over time and identify factors that may be associated with sleep disturbances in BC survivors. Patients and Methods Adult patients from the Mayo Clinic Breast Disease Registry were surveyed annually for up to 7 years post-diagnosis. Sleep disturbance severity was assessed using numeric rating scales for difficulty falling and staying asleep. Data from 3354 unique patients were analyzed, excluding those with metastatic disease or recurrence. Univariable and multivariable analyses were performed at the 1-year survey timepoint to evaluate disease and patient-related factors that were associated with increased sleep-related symptoms, and these factors were also assessed in relationship to sleep-related symptoms over time. Results In multivariable analyses, more trouble falling asleep was associated with financial insecurity, higher clinical stage, more cigarettes smoked per day, and less weekly exercise. More trouble staying asleep was associated with older age, race, advanced education, financial insecurity, and higher clinical stage. Over time, there was a nonsignificant trend toward increased trouble falling asleep and fluctuations in trouble staying asleep. Higher clinical stage and receipt of radiotherapy were associated with decreased severity in trouble falling asleep over time, while more cigarettes smoked per day was linked to increased severity in trouble staying asleep. Conclusions These findings highlight the complex interplay of clinical, lifestyle, and demographic factors in sleep disturbances among BC survivors, underscoring the need for tailored sleep management strategies.

This cross-sectional study analyzes patient-reported outcome findings from the Enhanced, Electronic Health Record–Facilitated Cancer Symptom Control (E2C2) trial to investigate level of symptom burden in adolescents and young adults with cancer.

Abstract Background Despite 40 years of evidence supporting psychosocial interventions as a component of comprehensive cancer care, patients continue to report vast unmet psychosocial needs and distress. Cognitive behavioral therapies for cancer distress (CBT-C) are the most rigorously tested class of psychosocial interventions for cancer care. Purpose To report clinical effectiveness outcomes of cancer-related distress and self-efficacy following implementation of best-evidence CBT-C, adapted for a real-world, billable practice setting. Methods Patients who completed group-delivered, CBT-C (10 intervention hours, 5 sessions) in the practice setting were invited to enroll in a research study to document cancer distress across the year following CBT-C. Participants (n = 65) were primarily middle-aged (mean 50.5 years, 17% were young adults ≤40 years), female, and White. Analyses utilized mixed linear models with intent-to-treat procedures. Given group delivery and social skills training content within CBT-C, social self-efficacy was assessed as a potential treatment mechanism. Results Distress decreased across the year following CBT-C (mean score change of 20 points for YAs, 6 points for non-YAs), with statistically significant age x time effects. Within-person improvements in social self-efficacy scores were related to reductions in cancer distress, including distress subscales of intrusive thoughts, avoidant coping, and hyperarousal. The model explained 76.6% of the total variance in cancer distress. Conclusions This study demonstrates the effective translation of CBT-C from controlled research trials to the practice setting. CBT-C effectiveness within a mixed-cancer population and relatively rural region of the US is also supported. CBT-C can be effectively translated to the practice settings for which it is intended.

1593 Background: “Financial toxicity” refers to the financial burden imposed by treatment costs on individuals with cancer, constituting a major barrier to achieving equitable cancer outcomes. Recent literature increasingly demonstrates the detrimental impacts of financial toxicity on quality of life (QOL) among individuals with cancer, including individuals who have undergone hematopoietic stem cell transplantation (HSCT). This study evaluates associations among treatment cost burden and various aspects of QOL following HSCT. Methods: Seven hundred one HSCT recipients completed a survey examining their biopsychosocial health one year following transplant. The survey included the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT), a multifactorial measure of QOL specific to this population. Treatment cost burden endorsement was measured on a 5-item Likert scale. Hierarchical regression models were developed to assess the incremental effects of demographic characteristics (i.e., Block 1), clinical predictors (Block 2), and cost burden (Block 3) on physical, emotional, social, functional, BMT-specific, general, and composite QOL outcomes. Results: Significant model improvement was observed with the addition of clinical factors ( ΔF(2,650) = 20.28, p < .001), and subsequently, treatment cost burden ( ΔF(1,649) = 110.29, p < .001). In the final model, higher cost burden was associated with poorer physical (β = -0.323, p < .001), emotional (β = -0.301, p < .001), social (β = -0.250, p < .001), functional (β = -0.317, p < .001), BMT-specific (β = -0.341, p < .001), general (β = -0.377, p < .001), and composite QOL (β = -0.381, p < .001). Poorer performance score was associated with each QOL indicator ( p < .001), with allogeneic transplant type associated with poorer functional (β = -0.001, p = .002), but higher emotional (β = 0.118, p = .002), wellbeing. Older age (β = 0.113, p = .003) and female sex predicted higher (β = 0.183, p < .001), while Hispanic ethnicity predicted poorer (β = -0.095, p = .010), social wellbeing. Female sex was associated with poorer QOL specific to BMT concerns (β = -0.118, p = .001). Conclusions: Higher treatment cost burden is associated with poorer overall QOL and its physical, emotional, social, functional, and BMT-specific components one year following HSCT, after controlling for demographic and clinical characteristics. This reflects a critical barrier to equitable cancer care, suggesting that financial toxicity may perpetuate preexisting inequities in QOL, treatment, disease, and survival outcomes that disproportionately impact the underserved. Future research should prioritize 1) better understanding relationships among complex indicators of financial toxicity, QOL, and their underpinning mechanisms and 2) developing solutions to mitigate financial toxicity of HSCT and overall cancer care.

12083 Background: Fatigue and sleep disturbance are prevalent during and after cancer treatment; sleep-related symptoms affect 30-50% of patients with cancer, and sleep-wake disruptions persist beyond the immediate post-surgical period in breast cancer (BC) survivors. Identifying demographic- and treatment-related factors associated with sleep-related symptoms during survivorship is critical to inform interventions for those at highest risk of sleep disturbance. Methods: Patients who were seen at least once at Mayo Clinic Rochester following an initial diagnosis of BC at age 18 or older and provided informed consent were prospectively enrolled in the Mayo Clinic Breast Disease Registry. Surveys mailed to this cohort included two 11-point numeric rating scale questions regarding difficulty falling asleep and staying asleep in the past week, with values for each ranging from 0 (no problem) to 10 (as severe as you can imagine). Participants who provided sleep-related information on the Year 1 survey (answered approximately one year after cancer diagnosis) were included. Participants were excluded if they had clinical or pathologic metastatic disease and/or recurrence prior to the Year 1 survey. Associations of sleep-related symptoms with demographic and clinical characteristics were assessed using multivariate linear regression models, fitting the sleep difficulty rating scale as the outcome and clinical and demographic factors as exposures. Results: In total, 3,354 participants met inclusion criteria. The average age at BC diagnosis was 59, and most participants were female (99.3%), White (95.4%), non-Hispanic (96.2%), married (78.1%), had at least some college education (80.4%), did not report financial insecurity (76.2%), did not consume alcohol (60.6%) or smoke tobacco (93.2%), and reported at least some weekly exercise (76,6%). Sixty-two percent of participants had clinical stage 0 or I disease; 50.3% underwent lumpectomy (not mastectomy), 59.2% received radiotherapy, 34.1% received chemotherapy, and 67.2% received endocrine therapy. Overall, sleep-related symptoms were relatively low (mean rating for falling asleep = 2.1, mean rating for staying asleep = 3.1). In multivariate analyses, more difficulty falling asleep was associated with higher clinical stage (p < 0.001), more cigarettes smoked per day (p = 0.012), less moderate and/or strenuous exercise (p = 0.001), and more financial hardship (p < 0.001). More difficulty staying asleep was associated with higher clinical stage (0.003), older age (p < 0.001), more education (p = 0.011), and more financial hardship (p < 0.001). Conclusions: In our cohort of BC survivors, factors associated with both increased difficulty with falling and staying asleep at one year after diagnosis are higher clinical stage and more financial hardship. Future research should explore the course of these symptoms over time and across varied treatment trajectories.

Objectives: Modifiable lifestyle factors are associated with morbidity and mortality in hematopoietic stem cell transplant (HSCT) survivors. The aims of the study were to examine: (a) receipt of provider advice to change behaviors, (b) health behavior change, and (c) how modifiable lifestyle factors might cluster together. Methods: Patients within a large HSCT program completed a survey (N =870) of lifestyle factors at pre-HSCT evaluation. The survey assessed self-reported adherence to American Cancer Society and HSCT guidelines for cancer survivorship in the year prior to a pre-HSCT evaluation. Lifestyle factors of interest were physical activity, fruit and vegetable consumption, tobacco use, alcohol use, and height/weight to calculate Body Mass Index (BMI). Results: Among patients not meeting all five guidelines (98%), 31% received provider advice to change. Between 10% and 42% reported healthy behavior change since diagnosis. Physical activity, fruit and vegetable consumption, and BMI were the most commonly clustered lifestyle behaviors. Conclusions: A considerable proportion of patients did not meet national guidelines for lifestyle factors. Results highlight an immediate opportunity to improve health care delivery and transplant outcomes via pre-HSCT lifestyle screening and implementation of effective health behavior change interventions.

Background: Breast cancer survivors face a risk of significant psychological distress, which can persist for years after their initial diagnosis. Although numerous guidelines and tools exist to help screen for and measure distress in patients with cancer, additional longitudinal studies are needed to better characterize the trajectory of distress over time. Patients and Methods: We conducted a longitudinal study to evaluate distress and health-related quality of life in patients with breast cancer. Annual assessments included global mental and physical health scores using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10), posttraumatic stress symptoms using the Impact of Event Scale-Revised (IES-R), and depressive symptoms using the Patient Health Questionnaire-2 (PHQ-2). Eligible participants had stage 0–III breast cancer, with baseline surveys administered within 1 year of diagnosis. Annual follow-up surveys were conducted through year 4 after the baseline survey. Only patients who completed the baseline survey and at least one follow-up survey were included in this analysis. Individuals with stage IV or recurrent breast cancer were excluded. Results: A total of 2,140 individuals were included. Over time, global mental health scores declined slightly, with differences in T-scores from baseline ranging from 0.4 to 0.9. In contrast, global physical health scores improved, with differences in T-scores ranging from 0.3 to 0.6. Mean scores remained in the normative range. Depressive symptoms remained stable throughout the study period, while posttraumatic stress symptoms showed improvement over time. Conclusions: This study provides important longitudinal data on distress subtypes in breast cancer survivors with nonmetastatic disease. Although global mental health declined slightly, depression symptoms remained stable, and posttraumatic stress symptoms improved. Investigation of distress subtypes over time merits further study to advance detection of significant distress across the cancer continuum.

ABSTRACTObjectiveTo explore pre–hematopoietic stem cell transplant (HSCT) demographic, disease, and psychological factors predictive of future transplant regret and to determine post‐HSCT variables associated with regret.Patients and MethodsHSCT candidates participated in a prospective cohort study (June 2008–October 2013) examining health behaviors and HSCT outcomes, including completion of standardized surveys at pre‐HSCT (baseline) and 1‐year post‐HSCT. Cases were participants that endorsed regret at 1‐year post‐HSCT follow‐up, and controls were participants without regret at 1 year, matched on age, sex, and transplant type. For cases and controls, pre‐HSCT psychosocial evaluations were abstracted from the electronic health record and coded to determine the Psychosocial Assessment of Candidates for Transplantation score, psychosocial stressors, and mental health diagnoses. The association of selected factors with regret was estimated with odds ratios and 95% confidence intervals from conditional logistic regression models.ResultsAt post‐HSCT, 49 participants of 638 endorsed transplant regret (8%) and formed the case group; 98 controls were matched from remaining participants. Cases and controls were well matched on age (56.6 vs. 57.2 years), sex (both groups 34.7% female), and transplant type (both groups 81.6% autologous). After controlling for the number of hospitalizations and active treatment status, conditional logistic regression revealed that patients who endorsed regret were 3.7 times (95% CI = 1.37–9.69, p = 0.008) more likely to not be in remission compared to controls at 1‐year post‐HSCT.ConclusionMatched case–control analyses revealed that no pre‐HSCT variables collected during the pre‐HSCT evaluation period were predictive of transplant regret, while poorer outcomes at 1‐year after transplant were associated with regret.